Rossari Biotech Limited — Important, 21-01-2025: Updates

The Board meeting has concluded with several key decisions impacting Rossari Biotech Limited. The company approved its unaudited financial results for the quarter and nine months ended December 31, 2024. Total revenue from operations was reported at ₹3,682.78 Cr, up from ₹2,987.52 Cr for the same period last year, showcasing strong growth. The net profit after tax stood at ₹306.31 Cr, reflecting consistent performance.

The Board also approved the relocation of the registered office within Mumbai, effective February 1, 2025. Additionally, the allotment of 7,500 equity shares under the Rossari Employee Stock Option Plan - 2019 has increased the paid-up equity share capital to ₹11,07,27,532.

Furthermore, M/s. Shah Patel & Associates has been appointed as the Secretarial Auditor for the financial year 2024-25, which is crucial for strengthening governance and compliance. This strategic move, combined with the positive financial results, paints a favorable outlook for the company's operational and financial health moving forward.